The Cholesterol Conversation: What Statins Can (and Can’t) Do for Aging Well
When we think about healthy aging, conversations often focus on exercise, nutrition, sleep, maintaining muscle, and managing blood pressure and blood sugar. Cholesterol is usually discussed in a different context: cardiovascular disease. But these topics are more connected than they might seem.
Atherosclerotic cardiovascular disease (ASCVD, or “heart disease”) develops over decades and can ultimately lead to heart attacks, strokes, disability, and loss of independence. Preventing these outcomes is therefore about more than adding years to life; it may also help preserve the years we spend living independently and functioning well.
This raises an important question: Can managing cholesterol help us age well?
Cholesterol: Essential, but it’s Complicated
Cholesterol often gets a bad reputation, but our bodies actually need it. It plays an important role in building cells, making hormones, and supporting normal body function. The problem isn’t cholesterol itself; it’s having too much of certain types circulating in the blood for too long.
One of the main types of cholesterol that has been focused on for many years is LDL, often called “bad cholesterol.” Over time, too much LDL can contribute to plaque building up inside the arteries. This process, known as atherosclerosis, can eventually restrict blood flow and cause a heart attack or stroke. The important point is that this is not an overnight process. It can develop silently over decades, which is why managing cholesterol can be part of thinking about long-term health.
This is one reason it can be helpful to look beyond a single cholesterol number. Rather than thinking of cholesterol as simply “good” or “bad,” it can be more helpful to think about how much cholesterol is in the blood and how long the body is exposed to it. The goal isn’t necessarily to have the lowest possible cholesterol, but to reduce the risk that cholesterol buildup will cause problems later in life.
Where Do Statins Fit In?
This is where statins come into the conversation. By lowering LDL cholesterol, statins can slow the buildup of plaque in the arteries and reduce the risk of heart attacks and strokes. The goal, therefore, isn’t simply to improve a cholesterol number, but to reduce the risk of cardiovascular disease that can ultimately lead to disability and loss of independence. Preventing these events may help preserve not only years of life, but also the quality and function of those years.
However, the potential benefit of a statin is not the same for everyone. For someone who has already had a heart attack, stroke, or other cardiovascular disease, the evidence supporting statin therapy is strong. For someone who has not yet developed cardiovascular disease, particularly an older adult, the decision is more individualized. Cardiovascular risk, other health conditions, frailty, medications, life expectancy, and personal goals can all influence whether a statin is likely to provide meaningful benefit.
This distinction is particularly important in older adults. The recently completed STAREE trial followed nearly 10,000 adults age 70 and older without cardiovascular disease, diabetes, or dementia for a median of 5.9 years. Those taking atorvastatin had a 30% lower risk of major cardiovascular events (heart attack, stroke, etc.), but the treatment did not significantly improve disability-free survival, which included death, dementia, or persistent physical disability. These findings suggest that while statins can reduce cardiovascular events in older adults, that benefit does not necessarily translate into longer periods of life free from disability or dementia. A limitation of these findings, however, is that STAREE excluded individuals with diabetes, chronic kidney disease, and elevated cholesterol. As a result, the findings may be less applicable to older adults with these conditions.
The decision also means weighing these potential benefits against the downsides of treatment. Statins are generally well tolerated, but some people experience unwanted effects, most commonly muscle aches. Because statins are intended to prevent problems that may occur years in the future, their benefits may also take time to become apparent. For an older adult, the question is therefore not simply, “Will a statin lower my cholesterol?” but “Is lowering my cardiovascular risk likely to help me live the kind of life I want to live?”
Do Statins Cause Dementia?
One of the most common concerns surrounding statins, which has been highlighted time and time again in popular culture, is whether lowering cholesterol could harm the brain.
The concern seems plausible at first. The brain contains a large amount of cholesterol, which is essential for normal brain function. If statins decrease cholesterol, could they deprive the brain of something it needs? However, the relationship between cholesterol in the blood and cholesterol in the brain is not this straightforward. The brain has its own tightly regulated cholesterol system that operates largely independently from cholesterol levels elsewhere in the body. Therefore, changes in blood cholesterol do not directly translate to changes in the brain’s cholesterol levels.
Current evidence does not support the claim that statins cause dementia. Randomized trials have not demonstrated that statins or other lipid-lowering therapies increase the risk of dementia or meaningful cognitive impairment. In addition, some observational studies have even found that statin users have a lower risk of dementia.
While there have been correlations between statin use and lower risk of dementia, due to the design of these studies, it cannot be established that statins prevent dementia. People who take statins may differ from those who do not in ways that are difficult to fully account for, including healthcare access, health behaviors, and other aspects of preventive care.
Therefore, the evidence does not justify either claim: “Statins cause dementia” or “Statins prevent dementia.”
Future Directions
To further explore the effect statins have on healthy aging, a large ongoing trial, PREVENTABLE, is studying whether statin therapy in adults 75 and older can affect outcomes including dementia, disability, and cardiovascular events. PREVENTABLE differs from STAREE in several important ways. It includes a broader population, allowing enrollment of people with conditions such as diabetes, chronic kidney disease, and elevated cholesterol that were excluded from STAREE. It also includes nearly twice as many participants, is being conducted across approximately 100 U.S. health-system and Veterans Affairs sites, and is intentionally enrolling a more diverse population, including greater representation of Black and Hispanic/Latino adults. These differences may help address some of the limitations of STAREE and provide insight into whether its findings apply to a broader population of older adults.
To learn more about PREVENTABLE, visit
https://clinicaltrials.gov/study/NCT04262206.
Cholesterol Is One Piece of Healthy Aging
With increasing discussion around cholesterol, it is important to approach healthy aging through a holistic lens. A 2025 analysis of cardiovascular risk factors found that modifying hypertension, diabetes, and smoking generally produced larger estimated gains in life expectancy and heart-disease-free years than lowering cholesterol alone. Exercise, healthy diet, blood pressure control, and avoiding tobacco remain fundamental components of healthy aging.
Statins are therefore not “anti-aging” drugs, and they cannot substitute for these behaviors. Instead, their use is more specific: to reduce the risk of cardiovascular events that can shorten life or compromise the years we spend living independently. Ultimately, the question isn’t whether statins are universally good or bad. It is whether lowering cardiovascular risk with a statin is likely to help a particular person achieve the kind of aging they value.
When thinking about cholesterol and statins, it’s important to remember that the goal isn’t simply to lower a number on a lab report. The goal is to preserve the years of life, independence, and function that make a longer life worth living.
References
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026.
- Alexander KP, Damluji AA, Erqou S, et al. Cognitive impairment and frailty in older adults with cardiovascular disease: 2026 ACC scientific statement: a report of the American College of Cardiology. J Am Coll Cardiol. 2026.
- Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020.
- Andersson NW, Corn G, Dohlmann TL, et al. LDL-C reduction with lipid-lowering therapy for primary prevention of major vascular events among older individuals. J Am Coll Cardiol. 2023.
- Ponce OJ, Larrea-Mantilla L, Hemmingsen B, et al. Lipid-lowering agents in older individuals: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2019. PMID: 30903687.
- Lucchi T. Lipid management. In: Pathy’s Principles and Practice of Geriatric Medicine. 6th ed. Wiley; 2022.
- Zhou Z, Ofori-Asenso R, Curtis AJ, et al. Association of statin use with disability-free survival and cardiovascular disease among healthy older adults. J Am Coll Cardiol. 2020.
- Awad K, Mohammed M, Zaki MM, et al. Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Med. 2021. PMID: 34154589.
- Orkaby AR, Driver JA, Ho YL, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020.
- Rea F, Biffi A, Ronco R, et al. Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy. JAMA Netw Open. 2021.
- Global Cardiovascular Risk Consortium; Magnussen C, Alegre-Diaz J, et al. Global effect of cardiovascular risk factors on lifetime estimates. N Engl J Med. 2025.
- Furrer R, Handschin C. Biomarkers of aging: from molecules and surrogates to physiology and function. Physiol Rev. 2025.
- Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Biological versus chronological aging: JACC focus seminar. J Am Coll Cardiol. 2020.
- Ni X, Su H, Lv Y, et al. Modifiable pathways for longevity: a Mendelian randomization analysis. Clin Nutr. 2023. PMID: 37172463.
- US Preventive Services Task Force; Mangione CM, Barry MJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022.
- Bittner V, Linnebur SA, Dixon DL, et al. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: an expert clinical consensus from the National Lipid Association and the American Geriatrics Society. J Am Geriatr Soc. 2025. PMID: 40207842.
- Zoungas S, Wolfe R, Moran C, et al. Atorvastatin, cardiovascular events, and disability-free survival in older adults. N Engl J Med. 2026. PMID: 42670961.
About the Author
Jeremy Ladd, MD Candidate, Class of 2028, University of Colorado School of Medicine, CSU Campus

